Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Our previous high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry study identified bladder cancer (BCA)-specific urine metabolites, including carnitine, acylcarnitines, and melatonin. The objective of the current study was to determine which metabolic pathways are perturbed in BCA, based on our previously identified urinary metabolome. Materials and Methods: A total of 135 primary BCA samples and 26 control tissue samples from healthy volunteers were analyzed. The association between specific urinary metabolites and their related encoding genes was analyzed. Results: Significant alterations in the carnitine-acylcarnitine and tryptophan metabolic pathways were detected in urine specimensfrom BCA patients compared to those of healthy controls. The expression of eight genes involved in the carnitine-acylcarnitinemetabolic pathway (CPT1A, CPT1B, CPT1C, CPT2, SLC25A20, and CRAT) or tryptophan metabolism (TPH1 and IDO1) was assessed by RT-PCR in our BCA cohort (n=135). CPT1B, CPT1C, SLC25A20, CRAT, TPH1, and IOD1 were significantly downregulatedin tumor tissues compared to normal bladder tissues (p<0.05 all) of patients with non-muscle invasive BCA, whereas CPT1B, CPT1C, CRAT, and TPH1 were downregulated in those with muscle invasive BCA (p<0.05), with no changes in IDO1 expression. Conclusion: Alterations in the expression of genes associated with the carnitine-acylcarnitine and tryptophan metabolic pathways, which were the most perturbed pathways in BCA, were determined.
Abstract
Purpose: Our previous high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry study identified bladder cancer (BCA)-specific urine metabolites, including carnitine, acylcarnitines, and melatonin. The objective of the current study was to determine which metabolic pathways are perturbed in BCA, based on our previously identified urinary metabolome. Materials and Methods: A total of 135 primary BCA samples and 26 control tissue samples from healthy volunteers were analyzed. The association between specific urinary metabolites and their related encoding genes was analyzed. Results: Significant alterations in the carnitine-acylcarnitine and tryptophan metabolic pathways were detected in urine specimensfrom BCA patients compared to those of healthy controls. The expression of eight genes involved in the carnitine-acylcarnitinemetabolic pathway (CPT1A, CPT1B, CPT1C, CPT2, SLC25A20, and CRAT) or tryptophan metabolism (TPH1 and IDO1) was assessed by RT-PCR in our BCA cohort (n=135). CPT1B, CPT1C, SLC25A20, CRAT, TPH1, and IOD1 were significantly downregulatedin tumor tissues compared to normal bladder tissues (p<0.05 all) of patients with non-muscle invasive BCA, whereas CPT1B, CPT1C, CRAT, and TPH1 were downregulated in those with muscle invasive BCA (p<0.05), with no changes in IDO1 expression. Conclusion: Alterations in the expression of genes associated with the carnitine-acylcarnitine and tryptophan metabolic pathways, which were the most perturbed pathways in BCA, were determined.
참고문헌 (33)
- Burger M, "Epidemiology and risk factors of urothelial bladder cancer", Eur Urol, 63, pp.234~241 (2013)
- van der Aa MN, "Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison", BJU Int, 101, pp.1106~1110 (2008)
- Lotan Y, "Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses", Urology, 61, pp.109~118 (2003)
- Putluri N, "Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression", Cancer Res, 71, pp.7376~7386 (2011)
- Liu X, "Differential toxicological effects induced by mercury in gills from three pedigrees of Manila clam Ruditapes philippinarum by NMR-based metabolomics", Ecotoxicology, 20, pp.177~186 (2011)
- Xu XJ, "2,4-Dihydroxypyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar disorder", Mol Biosyst, 10, pp.813~819 (2014)
- Garcia E, "Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe", J Proteome Res, 10, pp.1765~1771 (2011)
- OuYang D, "Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis", Appl Biochem Biotechnol, 165, pp.148~154 (2011)
- Mitra AP, "Strategies for molecular expression profiling in bladder cancer", Cancer Metastasis Rev, 28, pp.317~326 (2009)
- Alberice JV, "Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach", J Chromatogr A, 1318, pp.163~170 (2013)
- Huang Z, "Bladder cancer determination via two urinary metabolites: a biomarker pattern approach", Mol Cell Proteomics, 10, pp.M111~ (2011)
- Pasikanti KK, "Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry", J Proteome Res, 12, pp.3865~3873 (2013)
- Jin X, "Diagnosis of bladder cancer and prediction of survival by urinary metabolomics", Oncotarget, 5, pp.1635~1645 (2014)
- Rebouche CJ, "Modern Nutrition in Health and Disease", pp.505~512 (1999), Lippincott Williams and Wilkins
- Jogl G, "Crystal structure of carnitine acetyltransferase and implications for the catalytic mechanism and fatty acid transport", Cell, 112, pp.113~122 (2003)
- Reiter RJ, "Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions", Acta Biochim Pol, 54, pp.1~9 (2007)
- Babjuk M, "EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder", Eur Urol, 54, pp.303~314 (2008)
- Greene FL, "The American Joint Committee on Cancer: updating the strategies in cancer staging", Bull Am Coll Surg, 87, pp.13~15 (2002)
- Kim WT, "Identification of C16orf74 as a marker of progression in primary non-muscle invasive bladder cancer", PLoS One, 5, pp.e15260~ (2010)
- van der Leij FR, "Genomics of the human carnitine acyltransferase genes", Mol Genet Metab, 71, pp.139~153 (2000)
- Murthy MS, "Mechanism of carnitine acylcarnitine translocase-catalyzed import of acylcarnitines into mitochondria", J Biol Chem, 259, pp.9082~9089 (1984)
- Bieber LL, "Carnitine", Annu Rev Biochem, 57, pp.261~283 (1988)
- McKinney J, "Conformation of the substrate and pterin cofactor bound to human tryptophan hydroxylase. Important role of Phe313in substrate specificity", Biochemistry, 40, pp.15591~15601 (2001)
- Najfeld V, "Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12-->p11 by fluorescent in situ hybridization", Cytogenet Cell Genet, 64, pp.231~232 (1993)
- Bryan GT, "The role of urinary tryptophan metabolites in the etiology of bladder cancer", Am J Clin Nutr, 24, pp.841~847 (1971)
- Bansal N, "Low- and high-grade bladder cancer determination via human serum-based metabolomics approach", J Proteome Res, 12, pp.5839~5850 (2013)
- Tripathi P, "HR-MAS NMR tissue metabolomic signatures crossvalidated by mass spectrometry distinguish bladder cancer from benign disease", J Proteome Res, 12, pp.3519~3528 (2013)
- Wu XR, "Biology of urothelial tumorigenesis: insights from genetically engineered mice", Cancer Metastasis Rev, 28, pp.281~290 (2009)
- Adorno M, "A Mutant-p53", Smad complex opposes p63 to empower TGFbeta-induced metastasis, 2009, pp.137, 87~98
- Shariat SF, "Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma", Cancer, 92, pp.2985~2992 (2001)
- Derdak Z, "Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease", J Hepatol, 58, pp.785~791 (2013)
- Matoba S, "p53 regulates mitochondrial respiration", Science, 312, pp.1650~1653 (2006)
- Muller AJ, "Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy", Nat Med, 11, pp.312~319 (2005)